Know Cancer

forgot password

Study of Chemokine Markers and Genes as Predictors of Cardiovascular Disease

18 Years
Not Enrolling
Cardiovascular Disease

Thank you

Trial Information

Study of Chemokine Markers and Genes as Predictors of Cardiovascular Disease


Atherosclerosis is a chronic inflammatory disease classically triggered by hypertension,
diabetes, smoking and elevated cholesterol.

It is hypothesized that genetic predisposition plays a crucial role in an individual's
susceptibility to these risk factors with Single Nucleotide Polymorphisms (SNPs) being
identified as functional mediators of key inflammatory genes.


To determine the frequency of haplotypes of SNP combinations in the proximal promoter region
of MCP-1, the MCP-3 gene, and eotaxin gene in patients with risk factors for CVD and their

To determine the MCP-1 levels in an affected population with Coronary artery disease and
their siblings and certain haplotypes to determine a functional association between MCP-1
levels and haplotype frequency.


Eligibility criteria for enrollment in sib and family studies included: 1) having a sib or
1st degree family member with heart disease, 2) ability to give inform consent to
participate in the study, 3) age 18 years or older, 4) ability to speak English or Spanish.
The entire set of 2,000 samples available to the LDG will be analyzed. No subject will be


DNAs derived from properly consented subjects enrolled in three protocols sponsored by the
Johns Hopkins Heart Study will be sent to the LGD and used to test specific markers in the
MCP-1, MCP-3, and eotaxin chemokine family located in the C-C chemokine cluster on

A minimum of 11 SNPs will be examined.

Sib-pair analysis will be utilized to identify associated markers. Linear regressions will
be used to analyze associations between genetic variations and chemokine levels. Haplotype
will be assigned to unrelated individuals using the maximum likelihood approach.

The DNA samples, chemokine levels, and relevant clinical data provided by John Hopkins
University School of Medicine will be coded and linked.

Following this study, the DNAs will be maintained in our repository and curated through our
central Laboratory database. Loss or destruction of these samples will be annotated to our
database and cannot impact the study participants in any way. We understand that studies
subsequent to the completion of this protocol will require additional OHSR/IRB approval
prior to commencement.

Inclusion Criteria


Have a sibling or first degree family member with heart disease

Ability to give informed consent to participate in the study

Age 18 years or older

Ability to speak English or Spanish

Type of Study:


Study Design:


Principal Investigator

Janelle Cortner, Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)


United States: Federal Government

Study ID:




Start Date:

September 2005

Completion Date:

Related Keywords:

  • Cardiovascular Disease
  • Atherosclerosis
  • Single Nucleotide Polymorphisms
  • Monocyte Chemotactic Protein-1
  • Inflammation
  • Eotaxin
  • Cardiovascular Diseases



National Cancer Institute (NCI), 9000 Rockville PikeBethesda, Maryland  20892